Skip to content
Screener

Bioventus BVS Q1 2025 earnings

Reported May 6, 2025 · Before market open

Revenue$123.9MMiss by $22.0M
EPS$0.08Beat by $0.02
Revenue estimate$145.9M
EPS estimate$0.06

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$149.5M
EPS estimate$0.17

Financials

Q1 2025

Income statement

See full
Revenue$123.9M-4.3%
Gross profit$83.1M-6.0%
Operating income$4.9M-1.2%
Net income-$2.6M+46.1%
EPS (diluted)-$0.04+50.0%

Balance sheet

See full
Cash & equivalents$22.8M-9.4%
Total debt$366.1M-12.0%
Total equity$148.1M-13.5%
Total assets$691.4M-12.9%

Cash flow

See full
Operating cash flow-$19.3M-222%
CapEx$826.0K+184%
Free cash flow-$20.2M-220%

Valuation & ratios

Valuation

as of 03/29/25
See full
Market cap$605.34M+83.7%
Enterprise value$948.66M+31.7%
P/S1.1×+0.4×

Profitability

See full
Gross margin67.4%+1.9pp
Net margin-6%+4.3pp
FCF margin4.2%+3.7pp

Returns & leverage

See full
Return on equity-21.2%+59.3pp
Debt / equity2.5×0.0×
Current ratio1.4×-0.1×

Segments

By product

See full
Pain Treatments$58.9M+3.9%
Surgical Solutions$45.2M+7.0%
Restorative Therapies$19.7M-35.3%

By segment

See full
U.S. Segment$110.5M-3.3%
International Segment$13.4M-12.0%

By geography

See full
U.S.$110.5M—

FAQ

When did Bioventus report Q1 2025 earnings?
Bioventus (BVS) reported Q1 2025 earnings on May 6, 2025 before market open.
What were Bioventus's Q1 2025 revenue and EPS?
Bioventus reported revenue of $123.9M and eps of $0.08 for Q1 2025.
Did Bioventus beat estimates in Q1 2025?
Revenue missed the consensus estimate of $145.9M by $22.0M. EPS beat the consensus estimate of $0.06 by $0.02.
How did Bioventus's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 4.3% from $129.5M a year earlier and eps grew 14.3% from $0.07.
Where can I find Bioventus's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-022400) and the 10-Q periodic report (0001628280-25-022401) directly on SEC EDGAR. The filing index links above go to sec.gov.